Tango Therapeutics Inc (TNGX NASDAQ) stock market data APIs
$12.5546
0.05(0.4%)
as of February 11, 2026
Try our APIs with
free plan!
Tango Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Prev. Close
12.5546
Open
12.5791
High
12.6641
Low
12.1935
52 wk Range
1.03-13.46
Market Cap
1 698 M
Shares Outstanding
135 M
Revenue
66 501 K
EPS
-0.14
Beta
1.759
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tango Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tango Therapeutics Inc data using free add-ons & libraries
Get Tango Therapeutics Inc Fundamental Data
Tango Therapeutics Inc Fundamental data includes:
- Net Revenue: 66 501 K
- EBITDA: -107 913 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tango Therapeutics Inc News
New
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 0.7% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately –...
Revolution Medicines stock surges over 20% on potential AbbVie acquisition
Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock surged 29% before trading was halted twice due to volatility following a Wall Street Journal report that AbbVie (NYSE:ABBV) is in advanced tal...
Tango Therapeutics Appoints Sung Lee to Board of Directors
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision can...
Get Tango Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
